Cardiff Oncology Inc (CRDF)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $56.49M
Last updated: Nov 17, 2026 at 11:04 AM ET
Cardiff Oncology Inc (CRDF) Earnings: Report Dates and Results
Cardiff Oncology (CRDF) is expected to report earnings on Feb 22, 2027. In the quarter ended Sep 30, 2026, Cardiff Oncology reported EPS of -$0.12, above the -$0.14 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
CRDF has an expected report date of Feb 22, 2027.
CRDF Earnings Call
The latest CRDF earnings call transcript on file is labeled 2024Q4.
Read the 2024Q4 transcriptEarnings History
Of the 40 quarters below that had an estimate, CRDF beat 23, missed 12 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $171000, up 42.5% from $120000 a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.12 | -$0.14 | -$0.14 - -$0.12 | +14.29% | Beat | N/A | 4 | 4 up, 0 down | Nov 12, 2026 | $171000 |
| Jun 30, 2026 | -$0.14 | -$0.17 | N/A | +17.65% | Beat | N/A | 6 | 0 up, 5 down | Aug 11, 2026 | $104000 |
| Mar 31, 2026 | -$0.18 | -$0.12 | -$0.16 - -$0.11 | -50.00% | Miss | N/A | 5 | 3 up, 0 down | May 14, 2026 | $41000 |
| Dec 31, 2025 | -$0.11 | -$0.20 | -$0.26 - -$0.18 | +45.00% | Beat | N/A | 6 | 2 up, 0 down | Feb 24, 2026 | $243000 |
| Sep 30, 2025 | -$0.17 | -$0.21 | -$0.23 - -$0.19 | +19.05% | Beat | N/A | 6 | 1 up, 3 down | Nov 6, 2025 | $120000 |
| Jun 30, 2025 | -$0.21 | -$0.20 | -$0.22 - -$0.16 | -5.00% | Miss | N/A | 6 | 0 up, 1 down | Jul 29, 2025 | $121000 |
| Mar 31, 2025 | -$0.20 | -$0.19 | -$0.23 - -$0.14 | -5.26% | Miss | N/A | 5 | N/A | May 8, 2025 | $109000 |
| Dec 31, 2024 | -$0.21 | -$0.25 | -$0.29 - -$0.20 | +15.15% | Beat | N/A | 4 | 1 up, 0 down | Feb 27, 2025 | $150000 |
| Sep 30, 2024 | -$0.25 | -$0.27 | -$0.29 - -$0.26 | +7.41% | Beat | N/A | 5 | 0 up, 0 down | Nov 7, 2024 | $165000 |
| Jun 30, 2024 | -$0.26 | -$0.25 | N/A | -4.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2024 | $163000 |
| Mar 31, 2024 | -$0.22 | -$0.25 | -$0.27 - -$0.23 | +12.00% | Beat | N/A | 4 | 0 up, 0 down | May 2, 2024 | $205000 |
| Dec 31, 2023 | -$0.21 | -$0.28 | -$0.29 - -$0.27 | +25.00% | Beat | N/A | 4 | 0 up, 0 down | Feb 29, 2024 | $156000 |
| Sep 30, 2023 | -$0.22 | -$0.29 | -$0.32 - -$0.27 | +24.14% | Beat | N/A | 5 | 0 up, 0 down | Nov 2, 2023 | $141000 |
| Jun 30, 2023 | -$0.25 | -$0.25 | -$0.29 - -$0.23 | 0.00% | In line | N/A | 5 | 0 up, 0 down | Aug 9, 2023 | $108000 |
| Mar 31, 2023 | -$0.25 | -$0.22 | -$0.25 - -$0.21 | -13.64% | Miss | N/A | 5 | 0 up, 0 down | May 4, 2023 | $83000 |
| Dec 31, 2022 | -$0.20 | -$0.23 | -$0.30 - -$0.20 | +13.04% | Beat | N/A | 4 | 0 up, 0 down | Mar 2, 2023 | $128000 |
| Sep 30, 2022 | -$0.20 | -$0.24 | -$0.29 - -$0.24 | +16.67% | Beat | N/A | 5 | 0 up, 0 down | Nov 3, 2022 | $93000 |
| Jun 30, 2022 | -$0.24 | -$0.25 | N/A | +4.00% | Beat | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | $91000 |
| Mar 31, 2022 | -$0.25 | -$0.23 | -$0.25 - -$0.21 | -8.70% | Miss | N/A | 6 | 0 up, 0 down | May 5, 2022 | $74000 |
| Dec 31, 2021 | -$0.23 | -$0.17 | -$0.19 - -$0.14 | -35.29% | Miss | N/A | 6 | N/A | Feb 24, 2022 | $133000 |
| Sep 30, 2021 | -$0.17 | -$0.17 | -$0.19 - -$0.15 | 0.00% | In line | N/A | 4 | 1 up, 0 down | Nov 4, 2021 | $86000 |
| Jun 30, 2021 | -$0.17 | -$0.15 | -$0.17 - -$0.12 | -13.33% | Miss | N/A | 4 | N/A | Aug 5, 2021 | $68000 |
| Mar 31, 2021 | -$0.14 | -$0.15 | -$0.17 - -$0.12 | +6.67% | Beat | N/A | 4 | N/A | May 6, 2021 | $72000 |
| Dec 31, 2020 | -$0.08 | -$0.14 | -$0.15 - -$0.12 | +42.86% | Beat | N/A | 4 | N/A | Feb 25, 2021 | $119000 |
| Sep 30, 2020 | -$0.19 | -$0.19 | -$0.20 - -$0.17 | 0.00% | In line | N/A | 3 | N/A | Nov 5, 2020 | $136000 |
| Jun 30, 2020 | -$0.51 | -$0.24 | -$0.24 - -$0.24 | -112.50% | Miss | N/A | 1 | N/A | Aug 11, 2020 | $43000 |
| Mar 31, 2020 | -$0.41 | -$0.41 | N/A | 0.00% | In line | N/A | N/A | N/A | May 7, 2020 | $68000 |
| Dec 31, 2019 | -$0.51 | -$0.51 | N/A | 0.00% | In line | N/A | N/A | N/A | Feb 27, 2020 | $92576 |
| Sep 30, 2019 | -$0.71 | -$0.84 | N/A | +15.48% | Beat | N/A | N/A | N/A | Nov 7, 2019 | $51687 |
| Jun 30, 2019 | -$0.78 | -$1.02 | N/A | +23.53% | Beat | N/A | N/A | N/A | Aug 8, 2019 | $38348 |
| Mar 31, 2019 | -$1.02 | -$1.07 | N/A | +4.67% | Beat | N/A | N/A | N/A | May 7, 2019 | $62021 |
| Dec 31, 2018 | -$1.09 | -$1.05 | N/A | -3.81% | Miss | N/A | N/A | N/A | Mar 6, 2019 | $78015 |
| Sep 30, 2018 | -$1.08 | -$1.98 | N/A | +45.45% | Beat | N/A | N/A | N/A | Nov 7, 2018 | $88361 |
| Jun 30, 2018 | -$1.80 | -$1.98 | N/A | +9.09% | Beat | N/A | N/A | N/A | Aug 3, 2018 | $111813 |
| Mar 31, 2018 | -$6.06 | -$5.76 | N/A | -5.21% | Miss | N/A | N/A | N/A | May 8, 2018 | $100136 |
| Dec 31, 2017 | -$4.32 | -$9.00 | N/A | +52.00% | Beat | N/A | N/A | N/A | Feb 26, 2018 | $185026 |
| Sep 30, 2017 | -$8.64 | -$17.28 | N/A | +50.00% | Beat | N/A | N/A | N/A | Nov 9, 2017 | $123329 |
| Jun 30, 2017 | -$9.82 | -$23.04 | N/A | +57.38% | Beat | N/A | N/A | N/A | Aug 9, 2017 | $102011 |
| Mar 31, 2017 | -$19.44 | -$17.28 | N/A | -12.50% | Miss | N/A | N/A | N/A | May 10, 2017 | $95038 |
| Dec 31, 2016 | -$22.44 | -$23.04 | N/A | +2.60% | Beat | N/A | N/A | N/A | Mar 15, 2017 | $68072 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.69, after -$0.94 the year before. It was -$97.65 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.69 | N/A |
| Dec 31, 2024 | -$0.94 | N/A |
| Dec 31, 2023 | -$0.93 | N/A |
| Dec 31, 2022 | -$0.89 | N/A |
| Dec 31, 2021 | -$0.71 | N/A |
| Dec 31, 2020 | -$1.19 | N/A |
| Dec 31, 2019 | -$3.02 | N/A |
| Dec 31, 2018 | -$10.03 | N/A |
| Dec 31, 2017 | -$42.22 | N/A |
| Dec 31, 2016 | -$97.65 | N/A |
Earnings Calls
The 2 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 2,800 words across 9 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q4 | Dec 31, 2024 | 2,807 | 9 | |
| 2024Q2 | Jun 30, 2024 | 2,172 | 6 |
2024Q4 Earnings Call
Opening remarks
Kiki Patel Speaker Thank you, operator. Joining us on the call today from Cardiff Oncology, our Chief Executive Officer, Mark Erlander, and Chief Financial Officer, Jamie Levine. During this conference call, management will make forward-looking statements, including, without limitation, statements related to guidance, results, and the timing of data readouts for onvansertib clinical trials. These forward-looking statements are based on the company's current expectations and inherently involve significant risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties. Factors that could cause results to differ from these statements include factors the company described in the section titled Risk Factors in its annual report on Form 10-K filed with the SEC for the year ended December 31, 2024. Cardiff Oncology undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or changes in its expectations. With that, I turn the call over to Chief Executive Officer, Mark Erlander. Mark?
Mark Erlander CEO Thank you, Kiki, and good afternoon, everyone, and thank you for joining our business update conference call. The fourth quarter of 2024 was significant for Cardiff Oncology. On December 10, we released initial data from our ongoing CRDF-004 trial in first-line RAS-Mutated Metastatic Colorectal Cancer or mCRC, which we believe was highly encouraging and served as a basis for us to successfully complete a $40 million capital raise. On today's call, we will address four topics. First, we will briefly review the data we previously released from our lead program in mCRC and then provide an update on CRDF-004 enrollment activity and our registrational plans for onvansertib. Second, we will discuss our intellectual property strategy including the advances made in 2024 and what we expect for 2025. Third, we will share highlights from two preclinical posters we presented at the San Antonio Breast Cancer Symposium in December. Finally, we will discuss our financial position that we disclosed today in our Form 10-K filing. I begin with a review of the previously disclosed data from CRDF-004, which is our ongoing randomized Phase 2 trial in first-line RAS-mutated mCRC evaluating two dose levels of onvansertib combined with current standard of care regimens FOLFIRI or FOLFOX plus bevacizumab versus standard of care alone. In December, we released an initial data set as of November 26, 2024 for the first 30 patients on the trial. Overall, we were pleased with the efficacy signal observed in the trial. First, as of the data cutoff date, patients on the 30 mg dose of onvansertib demonstrated a 64% ORR compared to a 33% ORR in the control arm.
Frequently Asked Questions About CRDF
When is Cardiff Oncology's next earnings date?
Cardiff Oncology's next earnings report is expected for Feb 22, 2027.
Did CRDF beat earnings estimates last quarter?
Yes. Cardiff Oncology reported EPS of -$0.12 for the quarter ended Sep 30, 2026, above the -$0.14 estimate, a 14.29% surprise.
What EPS do analysts expect from CRDF next quarter?
The consensus EPS estimate for Cardiff Oncology for the quarter ending Dec 31, 2026 is -$0.16 from 9 analysts, with estimates from -$0.21 to -$0.09.
How often does CRDF beat earnings estimates?
Cardiff Oncology beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +6.36%.
CRDF pages: Overview, Earnings, Forecast, Financials, Competitors